Cite
MLA Citation
D Turner et al.. “DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn's disease: interim results of the CAPE registry.” Journal of Crohn's and colitis, vol. 12, n.d., p. S035. http://access.bl.uk/ark:/81055/vdc_100095509625.0x000012